1.825USD-6.65%Mkt Cap: 77.64M USDP/E: —Last update: 2026-06-01
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's dise…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap77.64M USD
Enterprise Value34.91M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.85M USD
Revenue/Share—
Last Price1.825 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS03615A1088
Valuation
P/E (Trailing)—
P/E (Forward)-1.66
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B17.45
EPS (TTM)-1.71
EPS (Forward)-1.16
52W Range
1.5407% of range5.500
52W High5.500 USD
52W Low1.540 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-171.23%
ROA-136.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.62M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-19.56%
Net Debt-19.53M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.80
Quick Ratio5.37
Book Value/Sh0.1100 USD
Cash/Share0.6890 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)12.50 USD
Target Range8.000 USD – 17.00 USD
# Analysts2
Ownership
Shares Out.42.54M
Float25.15M
Insiders14.10%
Institutions16.77%
Short Interest
Short Ratio4.8d
Short % Float15.15%
Short % Out.13.49%
Shares Short4.67M
Short (prev mo.)4.76M
Technical
SMA 502.074 (-12.0%)
SMA 2002.613 (-30.2%)
Beta1.26
S&P 52W Chg27.70%
Avg Vol (30d)1.12M
Avg Vol (10d)1.53M
Technical Indicators
RSI (14)44.0
MACD-0.0197
MACD Signal0.0013
MACD Hist.-0.0211
BB Upper2.444 USD
BB Middle2.152 USD
BB Lower1.860 USD
BB Width27.10%
ATR (14)0.1718 USD
Vol Ratio (20d)0.63x